Rituximab plus CHOP (R-CHOP) significantly improved the outcome of diffuse large B cell lymphoma (DLBCL), a common sub-type of non-Hodgkin lymphoma. The gene discussed is DDIT3; the disease is non-Hodgkin lymphoma.